New Delhi, Zydus Lifesciences Ltd on Wednesday said it has received final approval from the US health regulator to market generic sacubitril and valsartan tablet combination, used to treat chronic heart failure in adults.The approval by the US Food and Drug Administration (USFDA) is for the...
New Delhi, Zydus Lifesciences on Thursday said it has received provisional approval from the US health regulator to market generic azilsartan medoxomil tablets, used to treat high blood pressure.The provisional approval by the US Food and Drug Administration (USFDA) is for azilsartan medoxomil...
New Delhi: Zydus Group on Wednesday said it will make its antibiotic injection Biotax 1G available in Nepal with 10 ml of sterile water after that country's drug administration department objected to it not providing the solvent.Indian Pharmaceuticals Group refuted a media report that Nepal's...
New Delhi, Zydus Lifesciences Ltd on Friday said it has received provisional approval from the US health regulator to market azilsartan medoxomil and chlorthalidone tablets, which are indicated to treat high blood pressure.The provisional approval by the US Food and Drug Administration (USFDA)...
New Delhi, Zydus Lifesciences on Wednesday said it has received approval from the US health regulator to market a generic product for the treatment of asthma.The company has received final approval from the US Food and Drug Administration (USFDA) for the marketing of theophylline...
New Delhi, Zydus Lifesciences Ltd on Wednesday said it has received final approval from the US health regulator to market generic theophylline extended-release tablets, used in the treatment of asthma and chronic obstructive pulmonary disease.The approval by the US Food and Drug Administration...
New Delhi, Zydus Lifesciences on Friday said its consolidated net profit rose four times to Rs 1,182 crore in the fourth quarter ended March 31, 2024, due to higher sales.The pharmaceutical company had reported a net profit of Rs 297 crore in the January-March quarter of financial year...
New Delhi, Zydus Lifesciences Ltd on Friday announced an exclusive licensing supply agreement with MSN Laboratories for generic cancer treatment DR Cabozantinib tablets for the US market.The company's wholly-owned subsidiary, Zydus Lifesciences Global FZE, has entered into an exclusive...
New Delhi, Zydus Wellness Ltd on Tuesday reported 3.44 per cent rise in consolidated net profit at Rs 150.3 crore for the fourth quarter ended March 31, 2024.Zydus Wellness said in a regulatory filing that the company had posted a consolidated net profit of Rs 145.3 crore in the same quarter...
New Delhi, Zydus Lifesciences on Saturday said it has received approval from the US health regulator to sell a generic drug for arthritis and other conditions in the US market.The company has received final approval from the US Food and Drug Administration (USFDA) for the marketing of...
New Delhi, Zydus Lifesciences Ltd on Thursday said it has received final approval from the US health regulator to market the generic version of Dapsone Gel, used to treat acne.The final approval by the US Food and Drug Administration (USFDA) is for Dapsone Gel in 7.5 per cent strength, Zydus...
New Delhi: Zydus Lifesciences on Wednesday said the US health regulator has issued ten observations after inspecting its injection manufacturing plant in Gujarat's Vadodara.The US Food and Drug Administration (USFDA) inspected the facility at Jarrod Nia Vadodara from April 15 to April 23, the...
New Delhi, Zydus Lifesciences Ltd on Tuesday said its new drug Decidustat tablets, indicated for the treatment of anemia in patients with chronic kidney disease, has been accepted by the National Medical Products Administration of China.Discovered and developed by Zydus, Decidustat is being...
New Delhi, Zydus Lifesciences on Monday said it has launched a generic drug to treat overactive bladder in the US market.The company has launched Mirabegron extended-release tablets in the strength of 2 mg in the US market after receiving final approval from the US Food and Drug Administration...